secwatch.observer — SEC 8-K summary
======================================

Issuer:     Xilio Therapeutics, Inc. (XLO)
CIK:        0001840233
Form:       8-K
Filed at:   2024-08-08T23:59:59+00:00
Accession:  0001558370-24-011470
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Xilio Q2 net loss $13.9M; initiates Phase 2 for XTX101 in MSS CRC
-----------------------------------------------------------------

- Net loss $13.9M in Q2 2024 vs $19.4M in Q2 2023; R&D expenses $11.2M.
- Cash and equivalents $74.9M at June 30, 2024 (up from $44.7M Dec 2023); runway into Q2 2025.
- Initiated Phase 2 trial of XTX101 + atezolizumab in MSS CRC; data expected Q4 2024.
- Phase 1B dose expansion for XTX301 started; Phase 1A dose escalation ongoing with no DLTs.
- Promoted Chris Frankenfield to CFO while continuing as COO.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1840233/000155837024011470/0001558370-24-011470-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1840233/000155837024011470/xlo-20240808x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-24-011470

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer